AGN Allergan plc

138.87
-0.2  -0%
Previous Close 139.07
Open 138.6
Price To Book 0.66
Market Cap 46838900154
Shares 337,285,952
Volume 573,329
Short Ratio 1.49
Av. Daily Volume 3,229,278

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approval (third indication) announced October 3, 2017.
Botox
Forehead lines
Phase 2 data due 2019.
RTGel in combination with BOTOX
Overactive Bladder (OAB)
Approval announced March 20, 2017.
JUVÉDERM VOLLURE
Correction of moderate to severe facial wrinkles and folds
Phase 3 to be initiated 2H 2018 with data due 2020.
Brazikumab
Crohn's disease
Phase 3 enrollment to be completed 2H 2018.
Bimatoprost
Androgenic Alopecia
Phase 2 top-line data released April 5, 2017 - primary endpoint missed. Phase 3 planned.
Botox
Depression
Phase 3 data released December 18, 2017 - primary endpoint met.
Cariprazine
Bipolar I depression
Phase 2b trial ongoing.
RORγt agonist
Psoriasis
Approval announced November 13, 2017.
Cariprazine
Maintenance Treatment of Schizophrenia
Phase 3 Non-Hodgkin’s lymphoma expected 2019.
ABP 798
RITUXAN biosimilar - non-Hodgkin lymphoma
Phase 3 trial to be initiated 1H 2019 with data due in 2020.
ATOGEPANT
Prophylaxis (migraine)
Phase 3 initiated October 2016. Data due 1H 2019.
RAPASTINEL
Major depressive disorder (MDD)
Phase 3 initiated 2H 2017 with top-line data due 2020.
RELAMORELIN
Diabetic Gastroparesis
CRL issued August 21, 2018.
ESMYA (ulipristal acetate)
Uterine Fibroids
Phase 3 trial to be initiated 2019.
ABICIPAR
Diabetic macular edema (DME)
Phase 3 data due 2020.
Cenicriviroc (CVC)
Nonalcoholic steatohepatitis (NASH)
Phase 3 data released July 19, 2018. Primary endpoint met. BLA filing due 1H 2019.
ABICIPAR
Age-related macular degeneration (AMD)
sNDA acceptance announced October 11, 2016. Approval announced January 30, 2017.
AVYCAZ (ceftazidime and avibactam)
Complicated Urinary Tract Infections (cUTI)
Approved January 19, 2017.
Oxymetazoline HCl cream 1.0%
Facial Erythema (Redness) Associated with Rosacea
sNDA approval announced January 26, 2017.
Linaclotide 72 mcg dose for use in the treatment of adults
Chronic idiopathic constipation (CIC)
Approved September 14, 2017.
MVASITM (bevacizumab-awwb)
Biosimilar candidate to Avastin (bevacizumab)
FDA Approval announced October 2, 2018.
Sarecycline
Severe acne vulgaris
PDUFA date for sNDA filing May 2019.
Cariprazine
Bipolar I Depression
NDA filing due 1Q 2019.
UBROGEPANT
Migraine
Phase 2/3 data due 2020.
Brazikumab
Ulcerative colitis
Phase 3 trial to be initiated 2H 2018.
Brimo DDS
Geographic atrophy
NDA filing due 2H 2019.
Bimatoprost
Open-angle glaucoma or ocular hypertension

Latest News

  1. Appaloosa's Tepper says Allergan should consider selling itself
  2. CLASS ACTION UPDATE for DBVT, AGN, SVXY and GE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  3. CLASS ACTION UPDATE for GS, XRAY, NVDA and AGN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  4. Dentsply Sirona, Inc. (XRAY), The Goldman Sachs Group, Inc. (GS), Allergan plc (AGN) & JA Solar Holdings Co. Ltd. (JASO): Bronstein, Gewirtz & Grossman, LLC Announces Final Deadline
  5. Robert J. Hugin Appointed to Allergan Board of Directors
  6. Algernon Pharmaceuticals Begins Trading on The CSE Under The Symbol AGN
  7. ALLERGAN 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Allergan plc. - AGN
  8. FINAL DEADLINE ALERT - February 19, 2019 - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Allergan plc (AGN) and Lead Plaintiff Deadline
  9. What Analysts Are Recommending for Teva Pharmaceutical This Month
  10. FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Allergan plc (AGN) and Lead Plaintiff Deadline - February 19, 2019
  11. DEADLINE TOMORROW for GS, XRAY, NVDA and AGN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  12. CLASS ACTION UPDATE for XRAY, DBVT, AGN and GE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  13. CLASS ACTION UPDATE for DNKEY, YOGA, AGN and MHLD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  14. FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of XRAY, AGN, ALKS and SVXY
  15. CLASS ACTION UPDATE for XRAY, NVDA, AGN and YRIV: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  16. ALLERGAN 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess Of $100,000 of Deadline in Class Action Lawsuit Against Allergan plc. - AGN
  17. Allergan PLC (AGN) Files 10-K for the Fiscal Year Ended on December 31, 2018
  18. CLASS ACTION UPDATE for ARLO, AGN and UXIN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders